Amlodipine reverses the elevation in [Ca2+]i and the impairment of phagocytosis in PMNLs of NIDDM patients  by Krol, E.W.A. et al.
Kidney International, Vol. 64 (2003), pp. 2188–2195
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Amlodipine reverses the elevation in [Ca2+]i and the
impairment of phagocytosis in PMNLs of NIDDM patients
EWA KROL, RUBINA AGUEEL, SULTANA BANUE, MIROSLAW SMOGORZEWSKI, DINESH KUMAR,
and SHAUL G. MASSRY
Division of Nephrology and Division of Endocrinology, Diabetes and Hypertension, University of Southern California School,
Keck School of Medicine, Los Angeles, California
Amlodipine reverses the elevation in [Ca2+]i and the impair-
ment of phagocytosis in PMNLs of NIDDM patients.
Background. Patients with diabetes mellitus display an el-
evation in the basal levels of [Ca2+]i of polymorphonuclear
leukocytes (PMNLs) and impaired phagocytosis. These de-
rangements are due to the hyperglycemia of diabetes. Calcium
channel blockers reverse these abnormalities both in in vitro
studies and in diabetic rats. These observations suggest that cal-
cium channel blockers may be useful in the treatment of pa-
tients with uncontrolled diabetes. The present study examined
this issue.
Methods. A total of 32 normal subjects and 36 patients
with uncontrolled noninsulin-dependent diabetes mellitus
(NIDDM) were studied with and without treatment with
amlodipine both in a cross-sectional and longitudinal design
approach.
Results. In addition to the elevation in basal levels of [Ca2+]i
and the impaired phagocytosis, there was also down-regulation
of the mRNA of Fc c RIII receptors in the PMNLs of the di-
abetic patients. Treatment of the patients with a small dose of
amlodipine (5 mg/day) corrected these abnormalities despite
persistent hypoglycemia. This beneficial effect of nifedipine was
noted as long as the therapy with the drug was maintained.
Conclusion. The results show that the elevation in [Ca2+]i of
the PMNLs is associated with down-regulation of the mRNA
of their Fc c RIII receptors, which is at least, in part, responsi-
ble for the impaired phagocytosis. These derangements in the
metabolism and function of the PMNLs are most likely respon-
sible for the increased susceptibility of the diabetic patients to
infection. Calcium channel blockers may be a beneficial adjunct
therapy in patients with uncontrolled diabetes.
Available data have shown that the polymorphonu-
clear leukocytes (PMNLs) in patients with diabetes
mellitus display impaired phagocytosis [1, 2] as well as an
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elevation in the basal levels of their intracellular free cal-
cium concentration ([Ca2+]i). It was demonstrated that
these derangements are due to the hyperglycemia [3, 4].
Indeed, the normalization of blood glucose by an hypo-
glycemic agent in patients with noninsulin-dependent di-
abetes mellitus (NIDDM) was associated with the return
of both the level of [Ca2+]i in PMNLs and their phagocytic
property to normal [5]. Furthermore, both in vitro stud-
ies of PMNL incubated in hyperglycemic media [3] and in
vivo studies in rats with streptozotocin-induced diabetes
mellitus [4] showed that phagocytosis by the PMNL is
impaired and their [Ca2+]i is elevated.
The mechanisms through which hyperglycemia causes
a rise in [Ca2+]i have been studied in detail [3, 4].
Hyperglycemia causes shrinkage of the PMNLs, which
is sensed by a potential stretch receptor, which activates
several cellular pathways leading to stimulation of cal-
cium channels that permit calcium influx into the cells
and therefore causes an acute rise in [Ca2+]i. Indeed, var-
ious calcium channel blockers, including amlodipine, sub-
stantially ameloriated or completely abolished the rise in
[Ca2+]i of PMNLs despite persistent hyperglycemia. The
most effective calcium channel blocker in this regard was
amlodipine.
If impaired phagocytosis in patients with diabetes mel-
litus is due to the rise in [Ca2+]i, and if blood glucose is
difficult to control by diet, hypoglycemic agents and/or
insulin, it is tempting to suggest that the administration
of a calcium channel blocker to the patients may improve
or completely reverse the defect in phagocytosis irrespec-
tive of the blood levels of glucose. The present study
examined this issue in NIDDM patients with uncon-
trolled hyperglycemia.
METHODS
We studied 32 normal control subjects and 36 pa-
tients with NIDDM and poorly controlled blood glucose.
Among the control group were 12 females and 20 males
with their age ranging between 23 to 72 years [38 ± 2.1
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(SE) years]. They all had normal physical examination,
blood biochemistry, and renal function. The protocol of
the study and the informed consent form were approved
by the Institutional Review Board.
The diabetic patients were recruited from the diabetes
outpatient clinic of the Los Angeles County University
of Southern California Medical Center. The study was
offered to all NIDDM patients with poorly controlled
blood glucose. Only 36 consented to enroll into the study
and signed an informed consent form. The diagnosis of
NIDDM was made by the elevated fasting blood glucose
(>120 mg/dL) and absence of ketonemia [6]. The dura-
tion of diabetes from the time of diagnosis to the time of
the study ranged from 1 to 26 months (9 ± 1.5 months).
There were 27 females and 9 males among the diabetic
patients with their age ranging between 25 and 65 years
(49.5 ± 1.9 years). Their weight ranged between 54 and
136 kg (80 ± 3.3 kg) and their body mass index ranged
between 22 and 47 kg/m2 (30.5 ± 1.2 kg/m2) in the women
and between 24 and 41 kg/m2 (28.5 ± 1.9 kg/m2) in the
men. No patient had infection, nor was any receiving any
other medication except for the oral hypoglycemic agent,
glyburide.
Two types of studies were conducted in the patients.
Twenty-six patients were evaluated only once. Among
these there were nine patients already being treated with
amlodipine for the management of systolic hypertension.
Their blood pressure was 142 ± 6.0/76 ± 1.7 mm Hg.
The other 18 patients did not receive the calcium chan-
nel blocker and their blood pressure was 131 ± 6.0/71 ±
2.1 mm Hg. An additional 10 patients who were not
treated with a calcium channel blocker were evaluated
before and after 1 and 2 months of treatment with am-
lodipine (5 mg/day), as well as following 1 and 2 months
after cessation of therapy with amlodipine.
At each visit of the patients, a blood sample was
obtained for the measurement of glucose, hemoglobin
A1c (HbA1c), urea nitrogen (BUN), creatinine, calcium,
phosphorus, magnesium, parathyroid hormone, total
cholesterol and high-density lipoprotein (HDL) choles-
terol, and [Ca2+]i and phygocytic property of PMNLs.
Separation of PMNLs
Peripheral venous blood was drawn under sterile con-
ditions into vacutainers containing 20 U of preservative-
free heparin (Gibco Laboratories, Grand Island, NY,
USA) per 1.0 mL of blood. PMNLs were isolated from
whole blood according to the method described by
Ferrante and Thong [7]. Fresh heparinized blood was lay-
ered in 3.5 mL aliquots over Ficoll-Hypaque solution with
a density of 1.113 g/mL (Mono-Poly Resolving Medium)
(Flow Laboratories, McLean, VAUSA) and centrifuged
at 300g for 35 minutes at room temperature. This proce-
dure resulted in the separation of mononuclear and poly-
morphonuclear cells into two distinct bands, with the red
blood cell pellet at the bottom of the tube. The PMNL
layer was aspirated with a Pasteur pipette and washed
twice in Hank’s balanced salt solution. The purity of cells
as determined by Wright stain was greater than 97%, and
the viability of cells exceeded 98% as assayed by the try-
pan blue exclusion method.
Determination of phagocytosis
We estimated the rate of ingestion of PMNLs spec-
trophotometrically according to the bioassay described
by Southwick and Stossel [8]. Briefly, PMNLs were fed
oil droplets containing oil red O coated with Escherichia
coli lipopolysaccharide (2 mg per experiment). These par-
ticles were previously opsonized for 30 minutes in fresh
autologous serum (50% vol/vol). After the PMNLs and
the particles were incubated for 5 minutes at 37◦C, the
reaction was rapidly stopped by adding ice-cold isotonic
saline that contained 1 mmol/L N-ethylmaleimide, which
poisons the cells and stops ingestion. Uningested parti-
cles were separated from cells that contained ingested
particles by centrifugation at 250g for 10 minutes. Oil
red O was extracted from the cell pellet with dioxane,
and the optical density of the extract was measured
using a Perkin-Elmer Lambda 2 UV/VIS spectropho-
tometer (Perkin-Elmer, Norwalk, CT, USA) at a wave-
length of 525 nm. The ingestion rate was expressed in
micrograms of oil engulfed per 107 PMNLs per minute.
We purchased all reagents from Aldrich Chemical
(Milwaukee, WI, USA). Lipopolysaccharide E. coli
026:B6 was obtained from Bovin preparation (Difco Lab-
oratories, Detroit, MI, USA).
Measurements of cytosolic calcium
We measured resting levels of [Ca2+]i in PMNLs with
Fura 2-AM (Sigma Chemical Co., St. Louis, MO, USA).
A sample of 5 × 106 PMNLs was washed with solu-
tion 1, which contained 132 mmol/L sodium chloride,
3 mmol/L potassium chloride, 1 mmol/L magnesium sul-
fate, 1.2mmol/L monosodium acid phosphate, 5 mmol/L
D-glucose, 10 mmol/L Hepes, and 0.02 mmol/L calcium
chloride (pH was adjusted to 7.4 with Tris buffer) and
was then spun at 300g for 15 minutes. The pellet was
resuspended in 490 lL of Fura 2-AM dissolved in
dimethly sulfoxide, giving a final concentration of
4 lmol/L of Fura 2. The mixture was then incubated in
a water bath at 37◦C for 30 minutes. After this incuba-
tion, the cells were washed and resuspended in solution 1.
Cytosolic calcium levels were measured with Perkin-
Elmer fluorescence spectrophotometer (model LS 513)
at excitation wavelengths of 340 and 380 nm and an
emission wavelength of 510 nm, with slits of 10 mm and
20 mm, respectively. We added a 100 lL aliquot of the
PMNL suspension to a spectrophotometer cuvette that
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contained 1.9 mL of solution 2, which was the same as so-
lution 1 except that its calcium chloride concentration was
1 mmol/L. Autofluorescence from cells or added reagents
(or both) was monitored during each experiment and was
not found to be a significant factor. We evaluated maximal
fluorescence and minimal fluorescence with 0.05% Triton
and 56 mmol/L ethyleneglycoltetraacetic acid in Tris base
buffer (pH 8.0), respectively. Cytosolic calcium was cal-
culated using the equation of Grynkiewicz, Poenie, and
Tsien [9], and the dissociation constant for Ca2+-Fura 2
was assumed to be 225 nmol/L.
Measurement of gene expression of Fc c RIII
in PMNLs by reverse transcriptase-polymerase chain
reaction (RT-PCR)
RNA extraction. Total RNA was extracted by acid
guanidinium-phenol chloroform as described by Chom-
czynski and Sacchi [10] and later modified by them using
Trizol reagent [11]. The yields of RNA (lg/107 cells) from
the PMNLs of normal subjects (1.66 ± 0.26) and of di-
abetic patients without (1.63 ± 0.15) and with (1.52 ±
0.25) treatment of amlodipine were not significantly
different.
Reverse transcription (RT). Total RNA (1 lg in
5 lL) was mixed with 1 lL random hexamer primers
(0.5 lg/lL), incubated at 70◦C for 10 minutes, then trans-
ferred on ice for 5 minutes. Then, 14 lL of RT mixture
containing 2 lL 0.1 mol/L dithiothreitol (DTT), 1 lL
10 mmol/L desoxynucleoside triphosphate (dNTP) mix-
ture, 4 lL 5 × first-strand buffer; 1 lL Superscript II
(200 U/lL), and 6 lL diethyl pyrocarbonate (DEPC)
water were added to each tube. Thus, the total volume in
each tube was 20 lL. The tubes were incubated at 42◦C
for 1 hour, followed by 15 minutes at 70◦C, then chilled
on ice. One microliter of cDNA template was used for
each PCR.
Polymerase chain reaction (PCR). Primers used to am-
plify a 506 bp fragment encoding part of the transmem-
brane (TM) and 3′ untranslated (UT) regions of both Fc
c RIIIA and Fc c RIIIB genes were as follows: Fc c
RIII (sense) 5′-GTC TCT TTC TGC TTG GTG ATG
G-3′ (nucleotides 658–679) and Fc c RIII (antisense)
5′-TTT TCC CCT CTA AAC TGG G-3′ (nucleotides
1145–1164). The PCR assay was performed with 1 lg of
cDNA template as described above, 1 lL (0.2 mmol/L)
of each primer, 5 lL 10× PCR buffer, 1.5 lL 50 mmol/L
MgCl2, 1 lL 10 mmol/L dNTP, 0.5 lL Taq-cDNA poly-
merase (5 U/lL), 39 lL of DEPC water giving a total
volume of 50 lL. The first PCR cycle began with 4 min-
utes of denaturation at 95◦C followed by 11/2 minutes of
primer annealing at 55◦C and 21/2 minutes extension at
72◦C. This procedure was followed by 35 similar cycles
except that the denaturation time was 1 minute. In the
last cycle, the extension time was 5 minutes.
Samples of the PCR product were separated on 1%
agarose gel electrophoresis and stained with ethidium
bromide. Only PCR product with distinct target band
(506 bp) was used for further analysis. PCR for the
housekeeping gene b-actin was run under similar condi-
tions using primer 1 bases (268–289) 5′-TTC TAC AAT
GAG CTG CGT GTC G-3′ and primer 2 bases (806–783)
5′-ATA CCC AGG AAG GAA GGC TGG AAG, the
segment for PCR product was 539 bp.
Semiquantitation of RT-PCR. The RT-PCR products
were estimated according to the method of Higuchi and
Dollinger [12]. The PCR products (40 lL) were diluted
40 times with water. Ethidium bromide was added to a
final concentration of 250 ng/mL. Fluorescence was mea-
sured at 24, 28, 32, 36 cycles by a Hitachi spectrofluo-
rometer (Model F 2000) (Hitachi, Ltd., Tokyo, Japan), at
excitation wave of 280 nm and emission wave of 590 nm.
The amounts of Fc c RIII and of b-actin mRNA products
were determined, and the ratio of these measurements at
32 and 28 cycles, respectively, was calculated. These cycles
were chosen because they were the midpoint of the
exponential phase of the RT-PCR amplification. This
ratio represents the gene expression of Fc c RIII of
PMNLs.
Biochemical measurements
The concentration of calcium and magnesium in serum
was determined by Perkin-Elmer spectrophotometer
model 505 (Perkin-Elmer Corp.), phosphorus and cre-
atinine by an autoanalyzer (Technicon, Tarrytown,
NY, USA), serum glucose by a multichannel analyzer
(Beckman, Irvine, CA, USA), and HbA1c by an ion
exchange chromatography according to a modification
of the method of Trivelli et al [13]. The levels of to-
tal cholesterol and HDL cholesterol were measured by
standard method. Serum parathyroid hormone (PTH)
levels were estimated with radioisotopic assay (Intact
PTH-Nichols Institute Diagnostics). The normal values
of PTH in our laboratory are 10 to 42 pg/mL (25 ±
3.7 pg/mL).
Statistical analysis was done using a paired and an un-
paired t test and when applicable for comparison between
groups, one-way analysis of variance (ANOVA) was used.
The significance for the ANOVA analysis was deter-
mined with Bonferroni-Dunn t test. Data are reported as
mean ± SE.
RESULTS
Table 1 provides the clinical and biochemical data of
the diabetic patients at the time of the study. All patients
had uncontrolled diabetes as evidence by elevated lev-
els of fasting blood glucose and HbA1c. In the group
of patients who were studied only once, there were no
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Table 1. Clinical and biochemical profile of patients with
noninsulin-dependent diabetes mellitus (NIDDM)
Patients studied only once
Patients
studied
Without With prospectively
amlodipine amlodipinea for 4 months
Number of patients 17 9 10
Age years 55 ± 2.0 50 ± 3.1 50 ± 3.1
Male/female 6/12 1/18 3/7
Body mass index kg/m2 29 ± 2.2 33 ± 5.1 31 ± 1.6
Duration of NlDDM 10 ± 3.0 8 ± 1.9 10 ± 1.0
months
Blood pressure mm Hg
Systolic 131 ± 4.0 142 ± 6.0 140 ± 6.7
Diastolic 71 ± 2.1 76 ± 1.7 76 ± 2.8
Fasting glucose mg/dL 234 ± 14 237 ± 15 238 ± 21
Hemoglobin A1c%a 15.7 ± 0.8 14.6 ± 0.7 15.7 ± 0.8
Serum mg/dL
Blood urea nitrogen 13.5 ± 4.0 16.5 ± 2.6 16.4 ± 1.7
Creatinine 0.76 ± 0.04 0.74 ± 0.1 0.87 ± 0.07
Phosphorus 2.4 ± 0.12 2.5 ± 0.11 2.4 ± 0.12
Calcium 9.5 ± 0.15 9.1 ± 0.10 9.6 ± 0.13
Magnesium 1.8 ± 0.20 1.9 ± 0.07 1.7 ± 0.08
Total cholesterol 220 ± 15 188 ± 15 228 ± 15
HDL cholesterol 40 ± 3.0 43 ± 5.0 41 ± 4.5
PTH pg/mLa 34 ± 3.9 35 ± 5.8 27 ± 2.5
Abbreviations are: HDL, high-density lipoprotein; PTH, parathyroid hormone.
Data are presented as mean ± 1 SE. Duration of diabetes represents the period
elapsed between the time of diagnosis and the time of study. One patient in this group
was treated with felodipine and another with cardiazem.
aNormal value for PTH is 10 to 42 pg/mL; normal value of hemoglobin A1c is 4.0%
to 6.8%.
significant differences in all parameters between patients
who were and were not receiving amlodipine.
Table 2 gives the values of the biochemical parameters
before, during amlodipine therapy and after cessation of
treatment. The diabetic patients remained uncontrolled
during the 4 months of the study. There were no signifi-
cant differences between the fasting blood levels of glu-
cose and HbA1c as well as between all other biochemical
parameters.
The basal levels of [Ca2+]i in the PMNLs of normal sub-
jects ranged between 32 and 52 nmol/L (44 ± 1.1 nmol/L.
These values in the 17 diabetic patients who were not
receiving amlodipine ranged between 53 and 84 nmol/L
(64 ± 2.2 nmol/L) and were significantly (P < 0.01) higher
than normal values. In contrast, the values were normal
[range 39 to 59 nmol/L (46 ± 5.0 nmol/L)] in the diabetic
patients who were treated with amlodipine (Fig. 1).
The normal values of phagocytosis of PMNLs
ranged between 102 and 202 lg (139 ± 5.0 lg) oil/107
PMNLs/min. These values were significantly (<0.01)
higher than the values in the diabetic patients who were
not treated with amlodipine [range 50 to 117 lg (93 ±
4.0 lg)] oil/107 PMNLs/min (Fig. 2). Phagocytosis was
normal in the diabetic patients who were receiving am-
lodipine [range 119 to 158 lg (135 ± 5.4 lg)] oil/107
PMNLs/min.
Figure 3 depicts the results of the gene expression of
Fc c RIII of PMNLs in normal subjects and in diabetic
patients with and without treatment with amlodipine. The
ratio of Fc c RIII/b-actin mRNA in diabetic patients
without treatment with amlodipine (1.86 ±.034) was sig-
nificantly lower (P < 0.01) than that in normal subjects
(3.49 ± 0.31). In contrast, this ratio in the diabetic subjects
treated with amlodipine (3.01 ± 0.41) was significantly
higher (P < 0.01) than that in diabetic patients who were
not treated with amlodipine and not different from that
in normal subjects.
Figure 4 depicts the changes in the basal levels of
[Ca2+]i and in phagocytosis of PMNLs of diabetic patients
before, during amlodipine therapy, and after cessation of
the drug. In nine of the ten patients, the [Ca2+]i fell to
normal values from 70 ± 3.7 nmol/L to 45 ± 1.8 nmol/L
after 1 month of treatment. By the end of 2 months, all ten
patients had normal values of [Ca2+]i (41 ± 2.5 nmol/L).
After 1 month of cessation of treatment with amlodip-
ine, the [Ca2+]i of PMNLs rose to abnormal values in 9
of 10 patients (70 ± 4.1 nmol/L, P < 0.01) and remained
elevated after 2 months as well (67 ± 2.7 nmol/L). Both
of these values were not different from that before the
initiation of amlodipine therapy.
As the basal levels of [Ca2+]i began to fall after the
initiation of amlodipine therapy, phagocytosis rose in all
patients by the end of one month (from 87 ± 4.1 lg oil/107
PMNLs/min to 116 ± 7.3 lg oil/107 PMNLs/min) and
reached normal values by the end of 2 months (146 ±
5.4 lg oil/107 PMNLs/min). After 1 month of discontinu-
ation of the treatment with amlodipine, phagocytosis fell
to abnormal values (82 ± 3.5 lg oil/107 PMNLs/min) and
remained low by the end of 2 months as well (84 ± 3.0 lg
oil/107 PMNLs/min). The values of [Ca2+]i and phagocy-
tosis at 4 and 8 weeks were significantly different from
time zero, but the values at 12 and 16 weeks were not dif-
ferent from time zero (Fig. 4). In addition, the values of
both [Ca2+]i and phagocytosis at 4 and 8 weeks were sig-
nificantly different from the respective values at 12 and
16 weeks (P = 0.001).
DISCUSSION
The results of the present study demonstrate that pa-
tients with uncontrolled NIDDM treated with a small
dose of the calcium channel blocker amlodipine have nor-
mal [Ca2+]i of PMNLs and normal phagocytic property,
compared to elevated [Ca2+]i and impaired phagocyto-
sis of PMNLs from uncontrolled NIDDM patients who
were not treated with amlodipine. This effect of amlodip-
ine was observed despite no difference in the degree of
control of diabetes among the two groups (i.e., no signif-
icant different in the fasting blood levels of glucose or
HbA1c). Also, other factors that may affect [Ca2+]i and
phagocytosis of PMNLs such as chronic renal failure and
elevated blood levels of PTH [14] or phosphate deple-
tion [15] were not present in our patients since the blood
levels of PTH, phosphorus, and creatinine were normal
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Table 2. Biochemical data before, during 2 months of amlopidine therapy and during 2 months after cessation of therapy
During amlodipine After cessation of amlodipine
Months Months
Before amlodipine 1 2 1 2
Fasting glucose 238 ± 21 236 ± 47 198 ± 25 239 ± 32 205 ± 26
Hemoglobin A1c% 15.7 ± 0.8 15.2 ± 1.0 14.8 ± 0.8 14.2 ± 47 14.3 ± 0.7
Serum mg/dL
BUN 16.4 ± 1.7 14.4 ± 0.7 14.3 ± 0.8 14.4 ± 0.7 12.0 ± 1.4
Creatinine 0.87 ± 0.07 0.88 ± 0.08 0.80 ± 0.05 0.83 ± 0.07 0.90 ± 0.12
Phosphorus 2.4 ± 0.12 2.3 ± 0.13 2.3 ± 0.10 2.4 ± 0.1 2.4 + 0.12
Calcium 9.6 ± 0.13 9.4 ± 0.03 9.4 ± 0.09 9.5 ± 0.08 9.4 ± 0.10
Magnesium 1.8 ± 0.08 2.0 ± 0.05 1.9 ± 0.08 1.9 ± 0.03 1.8 ± 0.06
Total cholesterol 228 ± 15 194 ± 12 204 ± 23 212 ± 21 226 ± 19
HDL cholesterol 41 ± 4.5 36 ± 2.3 41 ± 4.1 41 ± 4.2 42 ± 4.0
Abbreviations are: BUN, blood urea nitrogen; HDL, high-density lipoprotein. Data are presented as mean ± 1 SE.
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Fig. 1. Cytosolic calcium of polymorphonuclear leukocytes (PMNLs)
from normal subjects, diabetic patients without and with treatment with
amlodipine. Each data point represents one patient and the brackets de-
note mean ± 1 SE. NIDDM is noninsulin-dependent diabetes mellitus.
and not different among the diabetic patients with or
without treatment with amlodipine. It is therefore rea-
sonable to propose that the normalization of [Ca2+]i
and phagocytosis of PMNLs of the patients treated
with amlodipine is related to an effect of the drug
itself.
Demerdash et al [3], using in vitro studies, delineated
the pathways through which a high glucose concentra-
tion induces a rise in [Ca2+]i of PMNLs. They found
that hyperglycemia activates multiple cellular pathways,
including the cyclic adenosine monophosphate (cAMP)-
protein kinase A system and phospholipase C pathway.
Both would activate calcium channels, which, in turn,
would permit calcium influx into the PMNLs. This cal-
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Fig. 2. Phagocytosis by polymorphonuclear leukocytes (PMNLs) ex-
pressed by the injection rate of oil particles from normal subjects and
from diabetic patients with and without treatment with amlodipine.
Each data point represents one patient and the brackets denote mean ±
1 SE. NIDDM is noninsulin-dependent diabetes mellitus.
cium influx was prevented by calcium channel blockers
such as verapamil and nifedipine. Similar effects were
also obtained with amlodipine [4]. In these latter stud-
ies, the elevation in [Ca2+]i of PMNL was associated with
impairment in their phagocytosis, and the normalization
of [Ca2+]i with the calcium channel blocker amlodipine
reversed the impaired phagocytosis.
The data of the present study are in agreement with the
in vitro data [3] and indicate that the interference with the
effect of hyperglycemia on the augmented calcium entry
into the PMNLs by a calcium channel blocker prevents
the hyperglycemia-induced derangements in [Ca2+]i and
phagocytosis of PMNLs of patients with NIDDM. These
human data in NIDDM are similar to those observed
in rats with streptozotocin-induced diabetes (IDDM)
[4]. Thus, the response of PMNLs to the calcium
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Fig. 3. The ratio of the mRNA of FC c RIII to b -actin in polymor-
phonuclear leukocytes (PMNLs) from normal subjects () and from
diabetic patients with () and without ( ) treatment with amlodipine.
The columns represent the mean values and the brackets denote mean ±
1 SE. ∗∗P < 0.01 vs. the other two groups.
channel blockers is not affected by the type of the diabetes
mellitus.
Our data also addressed the issue of the time required
for amlodipine to exert its effect and whether the effect
of amlodipine is a lasting one or it is present as long as the
treatment is maintained. Figure 4 shows that significant
improvement in [Ca2+]i of PMNLs and in their phagocy-
tosis occurred within a month of therapy with amlodipine
and normal values are achieved after 2 months of treat-
ment. The derangements in [Ca2+]i and phagocytosis of
PMNLs reemerged quickly within a month after discon-
tinuation of treatment with amlodipine. Thus, it is appar-
ent that treatment with amlodipine should be continued
in order to obtain a sustained beneficial effect on the
[Ca2+]i and phagocytosis of PMNLs of NIDDM patients.
All of the studies cited above indicate that the impaired
phagocytosis by the PMNLs from diabetic patients is me-
diated by the elevation in the basal levels of [Ca2+]i of
these cells.
Phagocytosis is the result of attachment of the bac-
teria and their engulfment by PMNLs. These cells pos-
sess receptors for IgG (Fc c RI-III) and for complement
(CR-1 and CR-3) [21, 22] and the activation of these
receptors mediates phagocytosis. The Fc c receptors uti-
lize calcium-dependent pathways [23]. Since the basal
levels of [Ca2+]i of PMNLs are elevated in diabetes mel-
litus, it is theoretically possible that this derangement in
the calcium homeostasis of these cells is associated with
abnormalities in the function and/or the number of their
Fc c receptors. Certain data are in agreement with this
proposition. We reported that in patients with chronic
renal failure in whom the [Ca2+]i of PMNLs is elevated,
the calcium signals in PMNLs induced by the ligation of
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Fig. 4. Changes in cytosolic calcium of polymorphonuclear leukocytes
(PMNLs) (A) and phagocytosis (B) observed in the 10 diabetic patients
before, during, and after cessation of nifedipine therapy. Each line rep-
resents one patient. These patients were hyperglycemic throughout the
entire period of the study and there were no differences in the blood
levels of fasting glucose and hemoglobin A1c at the various points of
the study (see Table 2).
their Fc c RIII receptors with 3G8 monoclonal antibodies
were significantly smaller than those observed in PMNLs
of normal subjects [14]. Also, the results of the present
study showed that the mRNA of the Fc c RIII receptors in
the PMNLs of diabetic patients is down-regulated. Taken
together, the data in chronic renal failure and in diabetic
patients indicate that the elevation in the basal levels of
[Ca2+]i is associated with reduced expression of Fc c RIII
receptors and/or in impairment in their function; either
or both abnormalities may play an important role in the
impaired phagocytosis of the PMNLs of the patients with
chronic renal failure and in those with diabetes mellitus.
Further support for this notion is found in the results
of the present study showing that normalization of the
[Ca2+]i in the PMNLs of the diabetic patients by their
treatment with amlodipine was associated with normal
values of their mRNA of Fc c RIII receptor and of their
phagocytic property.
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The mechanisms through which a rise in the basal lev-
els of [Ca2+]i of PMNLs cause down-regulation in the
mRNA of their Fc c RIII receptors are not delineated
by the present study. However, available data indicate
that an elevation in the basal levels of [Ca2+]i in many
disease settings is associated with down-regulation of the
mRNA of many receptors in a variety of cells. For exam-
ple, in chronic renal failure, the [Ca2+]i of almost every
cell is elevated [24]. Such an elevation is associated with
down-regulation of the mRNA of parathyroid hormone-
parathyroid hormone related protein (PTH-PTHrP) re-
ceptors in myocardial cells [25], kidney cells [26], and liver
cells [27]. Also, the mRNAs of angiotensin II and vaso-
pressin 1a receptors are down-regulated in liver cells [27]
from chronic renal failure animals.
Further, in the state of phosphate depletion in which
the basal levels of [Ca2+]i of cells are elevated, the mRNA
of PTH-PTHrP receptors is down-regulated [28]. In ad-
dition, Marcinkowski et al [29] found that in animals
with diabetes mellitus, the kidney cells whose [Ca2+]i
is elevated display down-regulation of several receptors,
including those of PTH-PTHrP, angiotensin II, and vaso-
pressin 1a.
The observations of the current study and those of the
in vitro investigation [3] and in diabetic rats [4] showing
that the effects of hyperglycemia on [Ca2+]i of PMNLs
is blocked by verapamil, nifedipine, and amlodipine im-
ply that PMNLs possess L-type calcium channels that
are inhibitable by calcium channel blockers. Certain data
suggest PMNLs may not have L-type calcium channel
[16]. However, Simchowitz and Spilberg [17] showed that
45Ca influx into PMNLs is inhibited by verapamil. Also,
Alexiewicz et al [18] and Ho¨rl et al [19] showed that treat-
ment of dialysis patients who also have elevated [Ca2+]i
of their PMNLs with verapamil or nifedipine was asso-
ciated with normalization of the [Ca2+]i in these cells.
Thus, the available data suggest that PMNLs have either
L-type calcium channel or other types of calcium channels
inhibitable by verapamil, nifedipine, or amlodipine [20].
An alternative explanation for the effect of amlodipine on
[Ca2+]i should also be considered. Hyperglycemia down-
regulates nitric oxide synthase and reduces the produc-
tion of nitric oxide [30]. These changes may be associated
with a rise in [Ca2+]i [31]. Calcium channel blockers up-
regulate the calcium-dependent nitric oxide synthase and
increase the production of nitric oxide both in in vivo [31]
and in vitro settings [32]. Such an increase in nitric oxide
may, through a nitric oxide-cyclic guanosine monophos-
phate (cGMP)–mediated mechanism, lower [Ca2+]i
[33, 34].
Our results provide evidence that one of the compli-
cations of diabetes mellitus [i.e., impaired metabolism
(elevated [Ca2+]i) and function (impaired phagocytosis)]
of PMNLs, could be reversed by treatment with a small
dose of amlodipine independent of the control of blood
glucose. Since impaired phagocytosis is one of the de-
rangements that may underlie the increased susceptibility
to infection in diabetes mellitus, our data may provide a
novel medical therapy for this complication of diabetes in
those patients in whom blood levels of glucose is difficult
to control.
It is of interest that Weinrauch et al [35] reported data
that provide support for the clinical relevance for the use
of calcium channel blockers to ameliorate the susceptibil-
ity to infection in diabetic patients. They found that sig-
nificantly fewer diabetic renal transplant patients treated
with a calcium channel blocker have sepsis and the num-
ber of septic episodes were significantly lower than in
a comparable group of diabetic transplant patients who
were not treated with a calcium channel blocker.
Taken together, the available data support the proposal
that patients with uncontrolled diabetes mellitus will ben-
efit from the use of small doses of a calcium channel
blocker and such medications may be a useful adjunct
therapy in diabetic patients with overt infection.
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